1. 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression. (December 2022) Authors: Rittmeyer, A.; Felip, E.; Altorki, N.K.; Vallieres, E.; Zhou, C.; Martinez-Marti, A.; Csoszi, T.; Reck, M.; Teixeira, M.E.; Deng, Y.; Huang, M.; McNally, V.A.; Bennett, E.; Gitlitz, B.J.; Srivastava, M.; Wakelee, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). (December 2022) Authors: Felip, E.; Srivastava, M.; Reck, M.; Wakelee, H.; Altorki, N.K.; Vallieres, E.; Liersch, R.; Harada, M.; Tanaka, H.; Hamm, J.T.; McCune, S.; Bennett, E.; Gitlitz, B.J.; McNally, V.A.; Novello, S.; Ballinger, M.; Zou, W.; Nabet, B.; Das Thakur, M.; Zhou, C. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). (September 2015) Authors: Horn, L.; Brahmer, J.; Reck, M.; Borghaei, H.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.J.; Burgio, M.A.; Fayette, J.; Gettinger, S.N.; Harbison, C.T.; Li, A.; Finckenstein, F.G.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3011 Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. (September 2015) Authors: Reck, M.; Coon, C.; Taylor, F.; DeRosa, M.; Penrod, J.R.; Dastani, H.; Orsini, L.; Gralla, R.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3032 A non-comparative, single-arm observational study conducted as a non-interventional study (NIS) to monitor the routine clinical practice of bevacizumab in combination with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in Germany. (September 2015) Authors: Wirtz, H.; Mezger, J.; Gaska, T.; Lerchenmueller, C.; Reck, M.; Reichert, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S606 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 3066 Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study. (September 2015) Authors: Joerger, M.; Von Pawel, J.; Kraff, S.; Fischer, J.R.; Gauler, T.; Mueller, L.; Reinmuth, N.; Reck, M.; Kimmich, M.; Frank, M.; Kopp, H.G.; Behringer, D.; Ko, Y.D.; Ralf, H.; Roessler, M.; Kloft, C.; Henrich, A.; Moritz, B.; Jaehde, U. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S618 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015) Authors: Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; Melemed, A.; Carter, G.C.; Zimmermann, A.H.; Treat, J.A.; Alexandris, E.; Lee, P.; Socinski, M.A.; Perol, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 3077 65 plus: A randomized phase III trial of Pemetrexed and Bevacizumab vs. Pemetrexed, Bevacizumab and Carboplatin as 1st line treatment for elderly patients with advanced non-squamous, non-small cell lung cancer (NSCLC) - a subgroup analysis of age and gender. (September 2015) Authors: Schuette, W.; Nieman, B.; Schneider, C.P.; Engel-Riedel, W.; Schumann, C.; Kohlhaeufl, M.; Serke, M.; Hoeffken, G.; Kortsik, C.; Reck, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results. (September 2015) Authors: Juhasz, E.; Ramalingam, S.; Blais, N.; Mazieres, J.; Reck, M.; Jones, M.; Urban, L.; Orlov, S.; Barlesi, F.; Kio, E.; Keilholz, U.; Qian, J.; Qin, Q.; Ansell, P.; Dziubinski, J.; Nickner, C.; McKee, M.; Giranda, V.; Gorbunova, V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC. (September 2015) Authors: Reck, M.; Ramalingam, S.; Blais, N.; Mazieres, J.; Jones, M.; Juhasz, E.; Urban, L.; Orlov, S.; Barlesi, F.; Kio, E.; Keilholz, U.; Qian, J.; Qin, Q.; Dziubinski, J.; Nickner, C.; Ansell, P.; McKee, M.; Giranda, V.; Gorbunova, V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗